Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nedlands, Australia, 6009
- Research Site 1
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Research Site 2
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Research Site 3
-
-
-
-
-
Christchurch, New Zealand, 8011
- Research Site 6
-
-
Auckland
-
Grafton, Auckland, New Zealand, 1010
- Research Site 4
-
-
Aukland
-
Papatoetoe, Aukland, New Zealand, 2025
- Research Site 5
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception
- Willing to provide written informed consent and to comply with study requirements
- On a stable diet for at least 4 weeks with no plans to significantly alter diet or weight over course of study
- Normal electrocardiogram (ECG) at Screening
Exclusion Criteria:
- Clinically significant health concerns
- Regular use of alcohol within one month prior to Screening
- Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study
- Recent use of illicit drugs
- Use of more than two tobacco/nicotine containing or cannabis products per month within 6 months prior to drug administration (applicable only to Normal Healthy Volunteers)
NOTE: additional inclusion/exclusion criteria may apply, per protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
calculated volume to match active treatment
|
|
Experimental: ARO-ANG3
|
single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment
Time Frame: Up to 113 (+/- 3 days) post-dose
|
Up to 113 (+/- 3 days) post-dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics (PK) of ARO-ANG3: Maximum Observed Plasma Concentration (Cmax)
Time Frame: Single dose phase: Up to 48 hours post-dose
|
Single dose phase: Up to 48 hours post-dose
|
|
PK of ARO-ANG3: Time to Maximum Plasma Concentration (Tmax)
Time Frame: Single dose phase: Up to 48 hours post-dose
|
Single dose phase: Up to 48 hours post-dose
|
|
PK of ARO-ANG3: Terminal Elimination Half-Life (t1/2)
Time Frame: Single dose phase: Up to 48 hours post-dose
|
Single dose phase: Up to 48 hours post-dose
|
|
PK of ARO-ANG3: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)
Time Frame: Single dose phase: Up to 48 hours post-dose
|
Single dose phase: Up to 48 hours post-dose
|
|
PK of ARO-ANG3: Area Under the Plasma Concentration Versus Time Curve From Zero to infinity (AUCinf)
Time Frame: Single dose phase: Up to 48 hours post-dose
|
Single dose phase: Up to 48 hours post-dose
|
|
Reduction in Fasting Serum ANGPTL3 from Pre-Dose Baseline
Time Frame: Baseline, Up to Day 113 (+/- 3 days)
|
Baseline, Up to Day 113 (+/- 3 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Ying Q, Chan DC, Watts GF. Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management. Curr Opin Lipidol. 2021 Jun 1;32(3):210-212. doi: 10.1097/MOL.0000000000000747. No abstract available.
- Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, Melquist S, Zhou R, Chang T, San Martin J, Gaudet D, Goldberg IJ, Knowles JW, Hegele RA, Ballantyne CM. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023 Sep;29(9):2216-2223. doi: 10.1038/s41591-023-02494-2. Epub 2023 Aug 25.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Hyperlipidemias
- Lipid Metabolism Disorders
- Lipid Metabolism, Inborn Errors
- Hyperlipoproteinemias
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Dyslipidemias
- Hyperlipoproteinemia Type II
- Hypertriglyceridemia
Other Study ID Numbers
Other Study ID Numbers
- AROANG1001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.